NanoViricides, Inc. — Form 10-Q Summary
Reporting-period note: The request identifies “2019 Q3,” but the supplied filing is for the quarter ended March 31, 2020, and reports the nine months ended March 31, 2020. The financial comparisons below use the periods stated in the filing.
Business context and reporting period
NanoViricides is a pre-revenue antiviral drug developer. Its lead program is NV-HHV-101, a topical shingles candidate, with other herpesvirus programs and a newly initiated COVID-19 program. The company relies on licensed technology from related party TheraCour Pharma and external collaborators for much of its drug development and testing. The unaudited report covers the three and nine months ended March 31, 2020; fiscal year-end is June 30.
Financial results and liquidity
| Metric | Three months ended March 31, 2020 | Nine months ended March 31, 2020 | Comparable 2019 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $1.13 million | $3.63 million | $1.31 million; $4.34 million |
| General and administrative expense | $1.41 million | $2.54 million | $0.77 million; $2.16 million |
| Operating loss | $2.54 million | $6.16 million | $2.08 million; $6.49 million |
| Net loss | $8.08 million | $11.57 million | $2.14 million; $6.21 million |
| Basic and diluted loss per share | $1.24 | $2.45 | $0.59; $1.77 |
| Net cash used in operating activities | Not provided for quarter | $5.11 million | Not provided for quarter; $5.13 million |
At March 31, 2020, cash and cash equivalents were $6.11 million, current assets were $6.44 million, current liabilities were $2.21 million, total assets were $16.53 million, and stockholders’ equity was $14.31 million. Accumulated deficit was $103.69 million. Net property and equipment was $9.71 million.
Cash increased by $3.55 million over the nine-month period, primarily reflecting $8.67 million in financing proceeds, including approximately $7.46 million net from a January common-stock offering. The company also drew $1.1 million under a mortgage note from its chairman, bearing 12% annual interest and secured by its headquarters; the reported balance net of unamortized fees was $1.07 million. A separate insurance-financing loan had a $109,295 balance. No revenue or operating margin is reported.
Changes versus prior comparable periods
- Nine-month R&D expense declined $706,483, which management attributed to lower external laboratory fees, staffing, and lab supplies.
- Nine-month G&A expense rose $379,972, primarily due to professional fees and other operating costs, partly offset by lower officer compensation and travel.
- Nine-month net loss increased $5.36 million, despite lower operating expenses. The principal driver was a $5.85 million non-cash expense from the change in fair value of warrant derivative liabilities; the comparable 2019 period recorded a $232,234 gain. The quarter’s $8.08 million net loss also included a $6.12 million derivative fair-value expense.
- Common shares outstanding rose to 7.67 million from 3.84 million at June 30, 2019, reflecting equity financing and other issuances. The filing also reports a one-for-twenty reverse stock split effective September 24, 2019.
Outlook, commentary, and risks
- Management said cash resources, including the subsequent May 2020 registered direct offering, were expected to fund planned operations for at least 12 months from issuance of the financial statements. The May offering raised approximately $9.3 million net. Further capital will be needed for longer-term operations and clinical development; future financing is not assured.
- The lead shingles candidate’s IND-enabling studies were described as substantially completed, with the IND application being prepared. The company gave no definite filing date and cited reliance on external collaborators, consultants, and COVID-19-related restrictions.
- Management said the company was prioritizing shingles and COVID-19 work while limiting other programs to conserve cash. Management’s development claims and timelines remain subject to preclinical results, regulatory review, funding, and execution risk.
- COVID-19 had not caused a direct financial impact as of the filing, but employee self-isolation and local restrictions disrupted laboratory work and contributed to delayed financial reporting. Management warned that prolonged market or economic disruption could impair access to capital.
- The filing discusses favorable company-reported COVID-19 cell-culture and animal-model results announced after the reporting period; these are not human clinical results. The company said additional studies and regulatory guidance would be needed before human trials.
- Material weaknesses in internal control over financial reporting remained unremediated at March 31, 2020, and management concluded disclosure controls were not effective. Remediation efforts included enhanced transaction review, outside specialists, and a financial reporting controls committee.
- Related-party matters include the chairman’s mortgage loan and TheraCour development fees and licenses. The VZV license includes milestone payments of $1.5 million, $2.5 million, and $5 million upon completion of Phases I, II, and III, respectively, plus 15% royalties on net sales.
- The company reported no pending legal proceedings to its knowledge and no off-balance-sheet arrangements during the nine months.
Important facts for investors to verify
- Confirm the reporting period: the filing is for March 31, 2020, not a 2019 third quarter.
- Review the warrant derivative accounting and the non-cash fair-value charge that materially affected reported losses.
- Track cash use, the May offering proceeds, the related-party mortgage maturity and extension, and the timing and terms of any additional financing.
- Verify progress toward the shingles IND filing, required regulatory steps, and whether reported COVID-19 findings are independently validated and advance into clinical testing.
- Assess the continuing internal-control material weaknesses, potential dilution from equity compensation and financing, and related-party arrangements with TheraCour and the chairman.